Unified Network for Integrated Fluid Collection at Yale
Part of paid clinical trials in New Haven, Connecticut.
- Sponsor
- Yale University
- Study ID
- NCT07689864
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Cancer
- Molecular Residual Disease
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Study Details
UNIFY is a Yale-wide liquid biopsy master repository that prospectively collects Streck-tube blood, dried blood spots (and optional archival tissue) from Yale Cancer Center patients across all tumor types for current and future research.
Key Dates
- First listed
- Jul 8, 2026
- Start date
- Aug 31, 2026
- Status verified
- Jul 2026
- Primary completion
- Aug 31, 2031
- Completion
- Aug 31, 2031
Study Design
- Enrollment
- 2,500 participants (estimated)
Arms
- Arm: UNIFYPatients enrolled in UNIFY only, with biological samples and limited clinical data collected as stipulated by this protocol
- Arm: UNIFY plusUNIFY plus a co-enrolled primary research study: Patients concurrently enrolled in a separate IRB-approved under UNIFY, limited clinical data will be collected for this cohort under the primary research study that requires blood sampling and optional or mandatory tumor tissue collection for research purposes.
Primary Outcome Measure
Collection and annotation of biospecimens [ Time Frame: Through study completion, up to 5 years ]
Central Contacts
- Mitchell Elliott, MD475-375-7981
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Smilow Cancer Hospital | New Haven | Connecticut | 06519 | - |
Find similar trials in New Haven, CT
By research site
Related Studies
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- Pan Tumor Rollover StudyPHASE2 · Recruiting · Bristol-Myers Squibb · Huntsville, Alabama
- TTX-080 HLA-G Antagonist in Subjects With Advanced CancersPHASE1 · Recruiting · Tizona Therapeutics, Inc · Tucson, Arizona
- Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067PHASE1/PHASE2 · Recruiting · Simcha IL-18, Inc. · Scottsdale, Arizona